Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 20;5(1):24.
doi: 10.3390/jof5010024.

Molecular Strategies to Diagnose Mucormycosis

Affiliations
Review

Molecular Strategies to Diagnose Mucormycosis

Laurence Millon et al. J Fungi (Basel). .

Abstract

Molecular techniques have provided a new understanding of the epidemiology of mucormycosis and improved the diagnosis and therapeutic management of this life-threatening disease. PCR amplification and sequencing were first applied to better identify isolates that were grown from cultures of biopsies or bronchalveolar lavage samples that were collected in patients with Mucorales infection. Subsequently, molecular techniques were used to identify the fungus directly from the infected tissues or from bronchalveolar lavage, and they helped to accurately identify Mucorales fungi in tissue samples when the cultures were negative. However, these tools require invasive sampling (biospsy, bronchalveolar lavage), which is not feasible in patients in poor condition in Hematology or Intensive Care units. Very recently, PCR-based procedures to detect Mucorales DNA in non-invasive samples, such as plasma or serum, have proved successful in diagnosing mucormycosis early in all patients, whatever the clinical status, and these procedures are becoming essential to improving patient outcome.

Keywords: Mucorales; PCR amplification; molecular diagnosis; mucormycosis; real-time quantitative PCR; sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Prakash H., Ghosh A.K., Rudramurthy S.M., Singh P., Xess I., Savio J., Pamidimukkala U., Jillwin J., Varma S., Das A., et al. A prospective multicenter study on mucormycosis in india: Epidemiology, diagnosis, and treatment. Med. Mycol. 2018 doi: 10.1093/mmy/myy060. - DOI - PubMed
    1. Kontoyiannis D.P., Yang H., Song J., Kelkar S.S., Yang X., Azie N., Harrington R., Fan A., Lee E., Spalding J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect. Dis. 2016;16:730. doi: 10.1186/s12879-016-2023-z. - DOI - PMC - PubMed
    1. Vallabhaneni S., Benedict K., Derado G., Mody R.K. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000–2013. Open Forum Infect. Dis. 2017;4:ofw268. doi: 10.1093/ofid/ofw268. - DOI - PMC - PubMed
    1. Bitar D., Lortholary O., Le Strat Y., Nicolau J., Coignard B., Tattevin P., Che D., Dromer F. Population-based analysis of invasive fungal infections, France, 2001–2010. Emerg. Infect. Dis. 2014;20:1149–1155. doi: 10.3201/eid2007.140087. - DOI - PMC - PubMed
    1. Guinea J., Escribano P., Vena A., Muñoz P., Martínez-Jiménez M.D.C., Padilla B., Bouza E. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS ONE. 2017;12:e0179136. doi: 10.1371/journal.pone.0179136. - DOI - PMC - PubMed

LinkOut - more resources